FDA Approves First At-Home Starting Dose for Leqembi in Early Alzheimer Disease

The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab-irmb (Leqembi), an amyloid beta-directed antibody indicated for adult patients with Alzheimer disease (AD). The agent was previously approved only as an intravenous (IV) starting dose, with an option to transition to IV or subcutaneous maintenance dosing after 18 months of treatment.¹

This action marks the first time patients can begin lecanemab treatment through home administration, performed by themselves or a caregiver, from the outset of therapy. The approval was granted to Eisai Inc and received priority review designation.¹

AD is an irreversible, progressive brain disorder that affects more than 6.5 million Americans. The condition gradually destroys memory and thinking skills and eventually impairs the ability to perform simple tasks. According to the FDA, the disease is characterized by the formation of amyloid beta plaques and neurofibrillary (tau) tangles in the brain, which result in the loss of neurons and their connections, although the specific causes are not fully understood.¹

The Studies Supporting the Approval

Lecanemab’s effectiveness was established in 2 large randomized, placebo-controlled clinical trials in patients with confirmed amyloid pathology and mild cognitive impairment (MCI) or mild dementia due to AD. In both studies, the evaluated dose was 10 mg/kg administered every 2 weeks by IV infusion over an 18-month treatment period, with an option for a longer-term follow-up phase.¹

The phase 3 trial, known as CLARITY AD (NCT03887455), enrolled 1795 participants between the ages of 50 and 90 years with early AD, randomly assigning 898 to receive IV lecanemab and 897 to receive placebo. According to the study, the trial's primary end point—change from baseline at 18 months on the Clinical Dementia Rating-Sum of Boxes (CDR-SB)—favored lecanemab, with an adjusted least-squares mean change of 1.21 for lecanemab compared with 1.66 for placebo (difference, -0.45; 95% CI, -0.67 to -0.23; P < .001).³

A substudy of 698 participants also showed greater reductions in brain amyloid burden with lecanemab than placebo (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6). Infusion-related reactions occurred in 26.4% of participants, and amyloid-related imaging abnormalities with edema or effusion (ARIA-E) occurred in 12.6%.³

These results built on an earlier phase 2b proof-of-concept trial (BAN2401-G000-201), in which 854 participants were treated with lecanemab or placebo using a Bayesian adaptive design. Although that trial's 12-month primary end point was not met, prespecified 18-month analyses showed a dose-dependent reduction in brain amyloid and consistent reductions in clinical decline across several measures, with ARIA-E incidence below 10% at the highest doses studied.⁴

Notably, the subcutaneous formulation of lecanemab was not tested separately in a large clinical outcomes trial. Instead, its approval is supported by the IV formulation's proven effectiveness together with pharmacokinetic evidence that the subcutaneous formulation produces equivalent systemic exposure and similar reductions in amyloid plaques as the IV formulation.¹

What This Means for Pharmacists

The shift toward home-based dosing raises new considerations for pharmacy teams involved in specialty dispensing, patient education, and safety monitoring. According to Appropriate Use Recommendations developed by the Alzheimer's Disease and Related Disorders Therapeutics Work Group, apolipoprotein E (APOE) ε4 genotyping is recommended for all lecanemab candidates before treatment initiation, since ε4 carriers—particularly homozygotes—face a substantially higher risk of ARIA.²

The FDA's prescribing information reinforces this, noting that patients homozygous for the APOE ε4 allele have a higher incidence of ARIA, including symptomatic, serious, and severe presentations.¹

The most common adverse effects of lecanemab are headache, infusion-related reactions, and ARIA. ARIA most often presents as temporary brain swelling visible on imaging, sometimes accompanied by small areas of bleeding, and although frequently asymptomatic, it can produce headache, confusion, dizziness, vision changes, or nausea.¹

In rare cases, ARIA can progress to serious, life-threatening brain edema associated with seizures or other severe neurologic symptoms, and intracerebral hemorrhage—a risk highlighted in the drug's boxed warning—can be fatal. The subcutaneous formulation, marketed as Leqembi IQLIK, is additionally associated with injection-site reactions such as redness, swelling, rash, pain, or bruising.¹

Use of anticoagulant medications was associated with an increased number of intracerebral hemorrhages among patients taking lecanemab compared with placebo, and the prescribing information recommends caution when considering the drug for patients on anticoagulant therapy or with other bleeding risk factors. Pharmacists reviewing medication profiles for patients on or considering lecanemab should flag concurrent anticoagulant use for prescriber discussion. Lecanemab is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or its inactive ingredients, and adverse reactions can include angioedema and anaphylaxis.¹

Access and Cost Considerations

Separate from the new starting-dose approval, background context from the Alzheimer's Association indicates that Leqembi carries a list price of $26,500 annually and that the Centers for Medicare & Medicaid Services covers the drug when a patient's physician enrolls them in a CMS-approved registry. Medicare-Medicaid dual-eligible individuals may also receive coverage for the 20% coinsurance portion through Medicaid, though state-level requirements may vary.⁵

REFERENCES

1. U.S. Food and Drug Administration. FDA Approves First At-home Starting Dose for Alzheimer's Disease Treatment. News release. FDA. July 13, 2026. Accessed July 13, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment

2. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. doi:10.14283/jpad.2023.30

3. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948

4. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80. doi:10.1186/s13195-021-00813-8

5. Alzheimer's Association. Lecanemab Approved for Treatment of Early Alzheimer's Disease. alz.org. Accessed July 13, 2026. https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi